ArticlePharmaceuticals (Basel, Switzerland)2021
GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma.Annals of medicine · 2023Pooled it
- A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.Gastroenterology · 2025Trial
- Validation of the GALAD model for diagnosing HBV-related hepatocellular carcinoma in Chinese patients.Clinics (Sao Paulo, Brazil) · 2026Article
- Assessment of GALAD score as a diagnostic and prognostic factor ofHepatology forum · 2026Article
- Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis.Cancers · 2025Article
- Current Tools to Diagnose and Predict Hepatocellular Carcinoma: Relevance to HIV and Hepatitis B Virus Coinfection.Current HIV/AIDS reports · 2025Review
- Article
- The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection.Diagnostics (Basel, Switzerland) · 2025Review
- The GALAD score performs better than AFP in hepatocellular carcinoma screening: a single-centre, case-control study in Malaysia.Clinical and experimental hepatology · 2025Article
- Comparative performance of the GAAD and ASAP scores in predicting early-stage hepatocellular carcinoma.Gastroenterology report · 2025Article
- GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease.The Cochrane database of systematic reviews · 2024Article
- Review
- Development and validation of a biomarker index for HCC treatment response.Hepatology communications · 2024Article
- The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2024Article
- A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies.Gastro hep advances · 2024Review
- Ensemble learning enhances the precision of preliminary detection of primary hepatocellular carcinoma based on serological and demographic indices.Frontiers in oncology · 2024Article
- Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.Journal of clinical laboratory analysis · 2023Article
- Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Evaluation of GALAD Score in Diagnosis and Follow-up of Hepatocellular Carcinoma after Local Ablative Therapy.Journal of clinical and translational hepatology · 2023Article
- Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.JGH open : an open access journal of gastroenterology and hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score, which incorporates gender, age, and serum levels of AFP, AFP isoform L3 (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), can improve early-stage HCC detection in a Caucasian HBV/HCV cohort. In a retrospective German single-center study, 182 patients with HBV, 223 with HCV and 168 with other etiology (OE) of chronic liver disease (CLD) were enrolled. HCC was confirmed in 52 HBV, 84 HCV and 60 OE CLD patients. The diagnostic performance of the single biomarkers in HCC detection was compared to the GALAD model. At initial diagnosis, most patients were at (very) early BCLC 0 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.